BR0312795A - Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca - Google Patents

Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca

Info

Publication number
BR0312795A
BR0312795A BR0312795-8A BR0312795A BR0312795A BR 0312795 A BR0312795 A BR 0312795A BR 0312795 A BR0312795 A BR 0312795A BR 0312795 A BR0312795 A BR 0312795A
Authority
BR
Brazil
Prior art keywords
preparation
sumatriptan
treating migraine
pharmaceutical presentation
processes
Prior art date
Application number
BR0312795-8A
Other languages
English (en)
Inventor
Rajeev Shankar Mathur
T Vijaya Kumar
Sunilendu Bhushan Roy
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0312795A publication Critical patent/BR0312795A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

"APRESENTAçãO FARMACêUTICA DE SUMATRIPTAN, PROCESSO PARA SUA PREPARAçãO E MéTODO PARA TRATAR A ENXAQUECA". O campo técnico da presente invenção se relaciona com comprimidos de sumatriptan com mascaramento de sabor, não-revestidos e processos para sua preparação. A invenção também se relaciona com comprimidos de sumatriptan polidos com cera e processos para sua preparação.
BR0312795-8A 2002-07-19 2003-07-17 Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca BR0312795A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN759DE2002 2002-07-19
PCT/IB2003/002838 WO2004009085A2 (en) 2002-07-19 2003-07-17 Taste masked sumatriptan tablets and processes for their preparation

Publications (1)

Publication Number Publication Date
BR0312795A true BR0312795A (pt) 2005-05-10

Family

ID=30471468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312795-8A BR0312795A (pt) 2002-07-19 2003-07-17 Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca

Country Status (7)

Country Link
US (1) US20060233875A1 (pt)
EP (1) EP1524978A2 (pt)
CN (1) CN1681493A (pt)
AU (1) AU2003249478A1 (pt)
BR (1) BR0312795A (pt)
RU (1) RU2005104827A (pt)
WO (1) WO2004009085A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
WO2010081136A1 (en) 2009-01-12 2010-07-15 Zentrum Mikroelektronik Dresden Ag Wide range charge balancing capacitive-to-digital converter
PT2663294E (pt) 2011-01-11 2016-01-25 Capsugel Belgium Nv Novas cápsulas duras contendo pululano
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
CN104739774A (zh) * 2013-12-26 2015-07-01 康普药业股份有限公司 一种琥珀酸舒马曲坦颗粒及其制备工艺
CN104906065A (zh) * 2014-03-13 2015-09-16 安阳天助药业有限责任公司 薄膜包衣光亮剂及制作工艺及制作光亮薄膜包衣方法
CN104480473B (zh) * 2014-11-14 2017-02-22 华中科技大学 一种固体缓蚀剂及其制备方法
JP7222911B2 (ja) 2017-04-14 2023-02-15 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ プルランを作製する方法
AU2018251256B2 (en) 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
GB2256648B (en) * 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
AUPO157396A0 (en) * 1996-08-09 1996-09-05 Aust Tech Pty. Ltd. Improvements in axial piston rotary engines
AU3596500A (en) * 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
WO2003053402A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
MXPA04008536A (es) * 2002-03-04 2005-09-08 Teva Pharma Forma de dosificacion de liberacion controlada.

Also Published As

Publication number Publication date
US20060233875A1 (en) 2006-10-19
AU2003249478A1 (en) 2004-02-09
WO2004009085A3 (en) 2004-05-13
CN1681493A (zh) 2005-10-12
RU2005104827A (ru) 2006-07-27
WO2004009085A2 (en) 2004-01-29
EP1524978A2 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
BR0312795A (pt) Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca
DE69634045D1 (de) Antithrombotische diamine
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
BR0307332A (pt) Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BR0015622A (pt) Processo de limpeza que utiliza ondas ultra-sÈnicas
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
PT1414816E (pt) Polimorfo estavel da flibanserina, processo tecnico para a sua preparacao e sua utilizacao na preparacao de medicamentos
BR0114344A (pt) Retinóides para o tratamento de enfisema
PT1060175E (pt) Inibidores de triptase
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
CR7198A (es) Tableta que contiene cetirizina y pseudoefedrina
NO20033318D0 (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
SE9501808D0 (sv) New process

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]